A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

632

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

March 30, 2026

Study Completion Date

November 30, 2026

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

TG103

TG103 injection, 7.5mg, 15 mg, SC, once a week

DRUG

Dulaglutide

Dulaglutide, SC, once a week

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY

NCT06235086 - A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter